Eyepoint Pharmaceuticals’ (EYPT) Hold Rating Reiterated at Laidlaw

Laidlaw reaffirmed their hold rating on shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) in a research report report published on Tuesday morning,Benzinga reports.

Other research analysts also recently issued reports about the company. Guggenheim downgraded Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Monday. HC Wainwright reiterated a “neutral” rating on shares of Eyepoint Pharmaceuticals in a report on Tuesday. TD Cowen cut Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating and reduced their price objective for the company from $20.00 to $4.00 in a research report on Wednesday, September 2nd. Mizuho restated a “neutral” rating and issued a $0.50 price objective on shares of Eyepoint Pharmaceuticals in a research note on Tuesday. Finally, Royal Bank Of Canada dropped their target price on shares of Eyepoint Pharmaceuticals to $1.00 and set a “sector perform” rating on the stock in a research report on Tuesday. Two research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Eyepoint Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $21.85.

Eyepoint Pharmaceuticals Stock Performance

Shares of NASDAQ:EYPT opened at $0.43 on Tuesday. The company has a market cap of $36.91 million, a P/E ratio of -0.11 and a beta of 1.67. The stock’s 50-day moving average is $3.99 and its 200-day moving average is $10.03. Eyepoint Pharmaceuticals has a 52-week low of $0.39 and a 52-week high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%. The business had revenue of $0.51 million for the quarter, compared to analyst estimates of $0.45 million. As a group, equities analysts predict that Eyepoint Pharmaceuticals will post -3.50 EPS for the current year.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

A number of hedge funds have recently made changes to their positions in EYPT. Cyndeo Wealth Partners LLC boosted its position in shares of Eyepoint Pharmaceuticals by 46.8% during the 3rd quarter. Cyndeo Wealth Partners LLC now owns 35,519 shares of the company’s stock valued at $116,000 after acquiring an additional 11,329 shares in the last quarter. Engineers Gate Manager LP bought a new stake in Eyepoint Pharmaceuticals in the second quarter valued at about $161,000. Integrated Wealth Concepts LLC bought a new stake in Eyepoint Pharmaceuticals in the second quarter valued at about $72,000. Squarepoint Ops LLC increased its stake in Eyepoint Pharmaceuticals by 22.3% in the second quarter. Squarepoint Ops LLC now owns 98,002 shares of the company’s stock valued at $1,401,000 after acquiring an additional 17,883 shares during the period. Finally, Baird Financial Group Inc. raised its position in Eyepoint Pharmaceuticals by 16.4% in the second quarter. Baird Financial Group Inc. now owns 32,732 shares of the company’s stock worth $468,000 after purchasing an additional 4,613 shares in the last quarter. Institutional investors and hedge funds own 99.41% of the company’s stock.

Key Eyepoint Pharmaceuticals News

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its Q3 2027 EPS forecast to $0.45 from a projected loss of $0.45, suggesting the analyst still sees a potential path to profitability in the longer term. However, the firm maintained a Neutral rating. HC Wainwright estimates
• Neutral Sentiment: Several firms maintained cautious views: HC Wainwright reaffirmed Neutral, Mizuho assigned Neutral, and Laidlaw reaffirmed Hold. These ratings indicate limited conviction in a near-term recovery following the clinical setback. HC Wainwright rating Mizuho rating Laidlaw rating
• Neutral Sentiment: Large call-option activity suggests some traders are positioning for a rebound, but options activity is speculative and does not change the company’s fundamental outlook. EyePoint call options
• Negative Sentiment: HC Wainwright reduced its Q3 2026 EPS estimate to a loss of $0.85 from $0.60 and cut its FY2026 estimate to a loss of $3.40 from $3.15, reflecting worsening near-term expectations. Revised EPS estimates
• Negative Sentiment: JPMorgan issued an Underweight rating, while Jefferies and Guggenheim downgraded the stock, adding further institutional pressure after the failed LUCIA trial. JPMorgan rating Jefferies downgrade Guggenheim downgrade
• Negative Sentiment: Levi & Korsinsky announced an investigation into potential securities claims related to the LUCIA trial disclosure and the resulting shareholder losses. The investigation adds legal and reputational risk, although it does not establish wrongdoing. Levi & Korsinsky investigation

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for serious eye diseases. The company specializes in sustained-release drug delivery for the retina and other parts of the eye, with the goal of reducing the frequency of injections and improving treatment convenience for patients.

EyePoint’s commercial products include YUTIQ, an injectable fluocinolone acetonide intravitreal implant used to treat chronic noninfectious posterior uveitis, and DEXYCU, an ophthalmic formulation of dexamethasone used to treat inflammation following ocular surgery.